Next Article in Journal
First International Electronic Conference on Medicinal Chemistry (ECMC-1)
Next Article in Special Issue
A Selenium Containing Inhibitor for the Treatment of Hepatocellular Cancer
Previous Article in Journal / Special Issue
Targeting Cell Survival Proteins for Cancer Cell Death
Open AccessShort Note

Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah’s Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia

School of Medicine, Marlene & Stewart Greenebaum Cancer Center, University of Maryland, 22 South Greene Street, Room N9E24, Baltimore, MD 21201, USA
Department of Pathology, School of Medicine, University of Maryland, Baltimore, MD 21201, USA
Author to whom correspondence should be addressed.
Academic Editor: Dhimant Desai
Pharmaceuticals 2016, 9(1), 12;
Received: 13 January 2016 / Revised: 19 February 2016 / Accepted: 8 March 2016 / Published: 10 March 2016
(This article belongs to the Special Issue Chemotherapeutic Agents)
Treatment of patients with acute myeloid leukemia (AML) who do not wish to accept blood product transfusion, including Jehovah’s Witnesses, is extremely challenging. The use of conventional chemotherapy for induction of complete remission (CR) results in profound anemia and thrombocytopenia requiring frequent transfusions of blood products, without which such treatment will be life-threatening. Finding a well tolerable, minimally myelosuppressive induction regimen for such patients with AML is a clear example of area of unmet medical need. Here, we report a successful treatment of a 52-year-old Jehovah’s Witness with newly diagnosed AML with peg-asparaginase, vincristine and methylprednisolone. The AML was characterized with normal karyotype, and mutations in isocitrate dehydrogenase 1 (IDH1-Arg132Ser), nucleophosmin 1 (NPM1-Trp289Cysfs*12) and neuroblastoma RAS viral oncogene homolog (NRAS-G1y12Va1). After one 28-day cycle of treatment, the patient achieved complete remission with incomplete count recovery (CRi) and after the second cycle, he achieved CR with full blood count recovery. The patient has never received any blood products. Notwithstanding that myeloperoxidase-induced oxidative degradation of vincristine results in its lack of activity as monotherapy in AML, its combination with corticosteroid and asparaginase has resulted in a robust remission in this patient. Diminished steroid clearance by asparaginase activity as well as reduction in serum glutamine level induced by glutaminase enzymatic activity of asparaginase may have contributed to effective killing of the myeloblasts that carry IDH1/NPM1/NRAS mutations. In conclusion, asparaginase-containing regimens, which are approved for treatment of acute lymphoblastic leukemia (ALL) but not AML, can be used to treat patients with AML who do not accept blood transfusion. View Full-Text
Keywords: acute myeloid leukemia (AML); isocitrate dehydrogenase (IDH); asparaginase acute myeloid leukemia (AML); isocitrate dehydrogenase (IDH); asparaginase
Show Figures

Figure 1

MDPI and ACS Style

Emadi, A.; Bade, N.A.; Stevenson, B.; Singh, Z. Minimally-Myelosuppressive Asparaginase-Containing Induction Regimen for Treatment of a Jehovah’s Witness with mutant IDH1/NPM1/NRAS Acute Myeloid Leukemia. Pharmaceuticals 2016, 9, 12.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop